... of multimodal treatment approaches over a 30-year period in 156 patients with advanced RCC treated with subcutaneous (s.c.) interleukin-2 (IL-2) and interferon-α (IFN-α) between 1990 and 2009. Results: The median progression-free survival following the first IT was 5.8 months with a wide range from 0 to 197...

...Kiminobu Arima; Masateru Nakagawa; Makoto Yanagawa; Yoshiki Sugimura; Hiromi Tochigi; Juichi Kawamura In 76 patients with renal cell carcinoma (RCC) we assessed the therapeutic effects of interferon-α (IFN-α) and the outcome of curative resection by analyzing changes in peripheral blood lymphocyte...

...Toshihiro S. Shimizu; Tatsuya Uchida; Yasuhiro Shibata; Jin Satoh; Shiro Sugihara; Yasunobu Maehara A 60-year-old man with renal cell carcinoma and metastases to the right 7th rib and L2 vertebra (T 2 N₀M 1 , OSS) was treated with interferon-α and the uracil and tegafur combination following...

... for such an approach. Patients and Methods: A retrospective analysis of 57 patients who received interleukin-2, interferon-α, and 5-fluorouracil immunochemotherapy for metastatic renal cell carcinoma was conducted. Before undergoing immunochemotherapy, 20 of the 57 patients had received metastatectomy along...

...Shinichi Ikemoto; Kazunobu Sugimura; Naomasa Yoshida; Katsuyuki Kuratsukuri; Seiji Wada; Tatsuya Nakatani Objectives: Although interferon-α (IFNα) and interleukin-2 are used in the treatment of advanced renal cell carcinoma (RCC), the rate of efficacy is about 15% and not satisfactory. Therefore...

...A.G. Papatsoris; C. Deliveliotis; A. Giannopoulos; C. Dimopoulos Objective: To determine the efficacy and safety of two different doses of intravesical mitoxantrone and of recombinant interferon-α (IFNα-2b), instilled after transurethral resection (TUR) of superficial transitional cell carcinoma...